Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Rodman & Renshaw 11th Annual Global Healthcare Conference

BUFFALO, NY--(Marketwire - August 31, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 11th Annual Global Healthcare...
August 17, 2009 09:22 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives First U.S. Patent Allowance for Its Radiation Protection Drug Protectan CBLB502

BUFFALO, NY--(Marketwire - August 17, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S....
July 01, 2009 08:00 ET | Source: Cleveland BioLabs, Inc.

Department of Defense Releases Further Funding to Cleveland BioLabs Under $8.8 Million Contract for Development Studies on Protectan CBLB502

BUFFALO, NY--(Marketwire - July 1, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint...
June 25, 2009 11:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Management Reviews Recent Highlights and Milestones at Annual Meeting

BUFFALO, NY--(Marketwire - June 25, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that Chief Executive Officer and President, Michael Fonstein, Ph.D. and Chief Scientific Officer,...
June 03, 2009 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Concludes Initial Phase I Safety and Tolerability Study for CBLB502

BUFFALO, NY--(Marketwire - June 3, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that dosing of healthy volunteers in the initial human safety study for CBLB502, a drug under...
May 28, 2009 09:41 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Submits Response to Department of Defense Sources Sought Notice for Radiological and Nuclear Medical Countermeasures

BUFFALO, NY--(Marketwire - May 28, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has responded to the Sources Sought Notice issued on May 5, 2009 by the Department of Defense...
May 21, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Signs Term Sheet for Joint Venture to Develop Curaxin Compounds for Cancer Applications

BUFFALO, NY--(Marketwire - May 21, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has signed a term sheet with Bioprocess Capital Ventures, a Russian venture capital fund, to...
May 18, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Oncogene Publishes Cleveland BioLabs Paper on Mechanism of Action of Curaxins

BUFFALO, NY--(Marketwire - May 18, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that new insights into the mechanism of action of the Company's first generation Curaxin anticancer...
May 15, 2009 14:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Formally Terminates Boston Stock Exchange Listing

BUFFALO, NY--(Marketwire - May 15, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company") today announced that in conjunction with the termination of the NASDAQ OMX BX (formerly known as the...
April 09, 2009 16:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Updates Financial Condition Following Completion of Private Placement and Streamlining of Operations

BUFFALO, NY--(Marketwire - April 9, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company"), in response to a request from the Listing Qualifications Staff of The NASDAQ Stock Market, is...